Companion Diagnostics For Targeted Therapies Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

8. 3.8. Product Pipeline Analysis

9. 3.9. Incidence and Prevalence Analysis

10. 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY COMPONENT

1. 5.1. Introduction

2. 5.2. Assays, Kits & Reagents

3. 5.3 Instruments

4. 5.4 Software & Services

6. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. Polymerase Chain Reaction (PCR)

3. 6.3. Next-Generation Sequencing (NGS)

4. 6.4. Immunohistochemistry (IHC)

5. 6.5. In Situ Hybridization (ISH)

6. 6.6. Gene Expression Profiling

7. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Cardiology

4. 7.4. Neurology

5. 7.5. Infectious Diseases

8. COMPANION DIAGNOSTICS FOR TARGETED THERAPIES MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 8.1. Major Players and Strategy Analysis

2. 8.2. Market Share Analysis

3. 8.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 8.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Roche Diagnostics

2. 10.2. Abbott Laboratories

3. 10.3. Thermo Fisher Scientific

4. 10.4. Agilent Technologies

5. 10.5. Qiagen

6. 10.6. Illumina

7. 10.7. Danaher Corporation

8. 10.8. Bio-Rad Laboratories

9. 10.9. Myriad Genetics

10. 10.10. Hologic

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES